Using a new PET/CT scan to diagnose glioma patients
68Ga-NOTA-RM26 PET/CT in Glioma Patients
EARLY_PHASE1 · Peking Union Medical College Hospital · NCT06412952
This study is testing a new type of PET scan to see if it can better diagnose and predict the severity of brain tumors called gliomas in patients who have not yet started treatment.
Quick facts
| Phase | EARLY_PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital (other) |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06412952 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of 68Ga-NOTA-RM26, a PET tracer that targets the gastrin-releasing peptide receptor (GRPR), in diagnosing high-grade gliomas and predicting their grade using PET/CT imaging. The study involves patients with suspected or confirmed untreated gliomas who will undergo this imaging technique to assess its clinical diagnostic value. The approach focuses on the over-expression of GRPR in glioma cells, aiming to improve diagnostic accuracy and treatment planning.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with suspected or confirmed untreated gliomas.
Not a fit: Patients who are pregnant, breastfeeding, or have known allergies to study components may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of glioma diagnosis and improve treatment strategies for patients.
How similar studies have performed: While the use of GRPR-targeting agents in imaging has shown promise in other cancers, this specific application in glioma is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * suspected or confirmed untreated glioma patients * signed written consent. Exclusion Criteria: * pregnancy * breastfeeding * known allergy against Pentixafor * any medical condition that in the opinion of the investigator,may * significantly interfere with study compliance
Where this trial is running
Beijing, Beijing Municipality
- Chinese Academy of Medical Science & Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Zhaohui Zhu
- Email: 13611093752@163.com
- Phone: +8613611093752
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Glioma